What Is Driving Alnylam Stock?
For questions about this article or underlying research, email help@trefis.com.
Alnylam Pharmaceuticals (ALNY) stock rose 5.4% on Friday, November 13, 2026, while the S&P 500 fell 0.4%. The company had no earnings report or SEC filing around the move. Health care stocks climbed that day, with the SPDR health care fund, XLV, up 0.5%. So what was going on in the market that Friday, and how does Alnylam’s business fit into it?

Alnylam Rose On A Day AI Stocks Slid
Artificial intelligence stocks slid again on November 13 amid turmoil at Nvidia, and the Nasdaq Composite fell 0.9% that session. Health care went the other way.
Alnylam is a health care company that earns its money from medicines. On its October 29 call, management said its TTR franchise, led by AMVUTTRA, brought in $1.15 billion of its roughly $1.3 billion in third-quarter product revenue.
Did Alnylam Move With Other Biotech Stocks?
Mostly not. Its sub-industry, biotechnology, finished flat. The 78 other companies in it worth $2 billion or more posted a median change of minus 0.1%. Of those, 37 rose and 41 fell, with just three climbing 5% or more, as Alnylam did.
Most of its peers rose, but most of them by much less. Four of Alnylam’s five peers rose, and Ionis Pharmaceuticals gained 6.4%, more than Alnylam, while Vertex Pharmaceuticals fell 0.7%. With its sub-industry flat, Alnylam moved largely on its own, alongside a few others such as Ionis.
Where Does Alnylam Stock Stand Now?
A rise this large is not rare for Alnylam, which had six in the prior 365 days, the latest on November 11. Even so, the stock has lost 63.5% over the past twelve months, against an 11.7% gain for the S&P 500. Friday’s close of $165.04 was near its lowest close of the year, $151.64 on November 10, and well below the high it reached on December 3, 2025, a close of $473.29.
Most of that loss came earlier, but the past month added to it. The stock is down 29.5% since October 15, and it fell 25.1% on October 29 alone, the day of its third-quarter call. On that call, management said it was not yet satisfied with the underlying demand growth, and it expected 2026 TTR product sales at the low end of its $4.2 billion to $4.5 billion range.
At 4.4 times its sales over the past twelve months, Alnylam is priced above the S&P 500’s 3.2 times. The company is expected to report its fourth-quarter 2026 results in February 2027, and management plans to give its first 2027 product revenue guidance with those results. That guidance is the figure to watch.
Want A Second Look At What You Own?
Alnylam Pharmaceuticals is one decision in a portfolio. Whether you work with an advisor or manage your money yourself, a second look at the whole portfolio costs nothing. Our partner advisory firm offers a free written review of your holdings, fees and income plan, with no need to switch.
Spot an error or want more like this? Tell us in 10 seconds.